search for


Long-Term Visual Outcomes in Patients with Neovascular AMD Who Exhibited Visual Acuity of 0.1 or Worse at 5th Injection
Journal of Retina 2018;3(2):64-70
Published online November 30, 2018
© 2018 The Korean Retina Society.

Kee Sun Tae1, Jong Woo Kim2, Chul Gu Kim2, Dong Won Lee2, Jae Hui Kim2

1Dr. Tae Eye Clinic, Seoul, Korea
2Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, Korea
Correspondence to: Jae Hui Kim, MD
Department of Ophthalmology, Kim’s Eye Hospital, #136 Yeongsin-ro, Yeongdeungpo-gu, Seoul 07301, Korea
Tel: 82-2-2639-7664, Fax: 82-2-2639-7824
Received May 21, 2018; Revised July 13, 2018; Accepted July 16, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose: To evaluate one-year follow-up outcomes of patients with neovascular age-related macular degeneration (AMD) who exhibited best-corrected visual acuity (BCVA) of 0.1 or worse at the 5th anti-vascular endothelial growth factor (VEGF) injection. The factors associated with visual prognosis were additionally investigated.
Methods: This retrospective study included 21 eyes (21 patients) diagnosed with neovascular AMD exhibiting BCVA of 0.1 or worse (0.1:13 eyes, worse than 0.1:8 eyes) at the 5th anti-VEGF (VEGF) injection. The timing of the 5th injection was identified. In addition, factors associated with 0.1 or better BCVA at 12 months after the 5th injection were investigated
Results: The timing of the 5th injection was a mean 9.1 ± 3.2 months after diagnosis. The mean logarithm of minimal angle of resolution BCVA at the 5th injection and at 12 months after was 1.14 ± 0.20 and 1.21 ± 0.40, respectively. At 12 months after the 5th injection, 8 eyes (38.1%) and 3 eyes (14.3%) exhibited BCVA of 0.1 and 0.2, respectively. The BCVA at the 5th injection was significantly associated with that measured at 12 months after (p = 0.008).
Conclusions: In eyes exhibiting BCVA of 0.1 or worse at the 5th injection, visual acuity was not significantly changed during 12-months of treatment, and the BCVA at the 5th injection was predictive of the 12-month visual outcome. Visual improvement was noted in some eyes, suggesting the need for continuous treatment for these eyes.
Keywords : Aflibercept; Age-related macular degeneration; Anti-vascular endothelial growth factor; Choroidal neovascularization; Ranibizumab

November 2018, 3 (2)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)
  • CrossMark
  • Crossref TDM